Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Shafrin

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Advances in Therapy|January 6, 2022
White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an ExampleChristian Jackisch, Federico Manevy, Suzanne Frank, et al.
Journal of Medical Economics|August 15, 2022
Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulatorsErvant J Maksabedian Hernandez, Marlon Graf, Alexandria Portelli, et al.
Schizophrenia Research|March 19, 2026
Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperativeArundati Nagendra, Raquelle Mesholam-Gately, Jason Shafrin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Patient Versus Physician Valuation of Durable Survival Gains: Implications for Value Framework AssessmentsJason Shafrin, Taylor T Schwartz, Tony Okoro, et al.
Journal of Managed Care & Specialty Pharmacy|October 27, 2016
Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with SchizophreniaJason Shafrin, Taylor T Schwartz, Darius N Lakdawalla, et al.
The American Journal of Managed Care|January 2, 2025
Impact of delayed adoption of novel atrial fibrillation treatmentsJaehong Kim, Jeremy Nighohossian, Anastasia G Daifotis, et al.
Journal of Managed Care & Specialty Pharmacy|July 11, 2024
How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetesJason Shafrin, Shanshan Wang, Jaehong Kim, et al.
Journal of Medical Economics|September 18, 2020
Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failureJason Shafrin, Elmar R Aliyev, Michelle Brauer, et al.
Health Economics|September 14, 2016
Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity DisorderJason Shafrin, Anshu Shrestha, Amitabh Chandra, et al.
Schizophrenia Research|April 16, 2026
Corrigendum to "Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperative" [Schizophr. Res. Volume 292, June 2026, pages 96-102]Arundati Nagendra, Raquelle I Mesholam-Gately, Jason Shafrin, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Advances in Therapy|January 6, 2022
White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an ExampleChristian Jackisch, Federico Manevy, Suzanne Frank, et al.
Journal of Medical Economics|August 15, 2022
Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulatorsErvant J Maksabedian Hernandez, Marlon Graf, Alexandria Portelli, et al.
Schizophrenia Research|March 19, 2026
Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperativeArundati Nagendra, Raquelle Mesholam-Gately, Jason Shafrin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Patient Versus Physician Valuation of Durable Survival Gains: Implications for Value Framework AssessmentsJason Shafrin, Taylor T Schwartz, Tony Okoro, et al.
Journal of Managed Care & Specialty Pharmacy|October 27, 2016
Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with SchizophreniaJason Shafrin, Taylor T Schwartz, Darius N Lakdawalla, et al.
The American Journal of Managed Care|January 2, 2025
Impact of delayed adoption of novel atrial fibrillation treatmentsJaehong Kim, Jeremy Nighohossian, Anastasia G Daifotis, et al.
Journal of Managed Care & Specialty Pharmacy|July 11, 2024
How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetesJason Shafrin, Shanshan Wang, Jaehong Kim, et al.
Journal of Medical Economics|September 18, 2020
Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failureJason Shafrin, Elmar R Aliyev, Michelle Brauer, et al.
Health Economics|September 14, 2016
Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity DisorderJason Shafrin, Anshu Shrestha, Amitabh Chandra, et al.
Schizophrenia Research|April 16, 2026
Corrigendum to "Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperative" [Schizophr. Res. Volume 292, June 2026, pages 96-102]Arundati Nagendra, Raquelle I Mesholam-Gately, Jason Shafrin, et al.
Pageof 9